Try our Advanced Search for more refined results
In re Solodyn (Minocycline Hydrochloride) Antitrust Litigation
Case Number:
1:14-md-02503
Court:
Nature of Suit:
Multi Party Litigation:
Class Action, Multi-district Litigation
Judge:
Firms
- Weinstein Kitchenoff
- Berman Tabacco
- Post & Schell
- Harkins Cunningham
- Hilliard & Shadowen
- Girard Sharp
- Coppersmith Brockelman
- Hach Rose Schirripa
- Hogan Lovells
- Morrison Mahoney
- Cohen Placitella
- Goldman Scarlato
- Pomerantz LLP
- Faruqi & Faruqi
- Blish & Cavanagh
- Demeo LLP
- Hagens Berman
- Goodwin Procter
- Shapiro Haber
- Robins Kaplan
- Kirkland & Ellis
- Andrews DeValerio
- Simmons Hanly
- Motley Rice
- Mintz Levin
- O'Melveny & Myers
- FrancoLaw PLLC
- Kessler Topaz
- Osborn Maledon
- Dugan Law Firm
- Stevens & Lee
- Lowenstein Sandler
- Radice Law Firm
- Hausfeld LLP
- Hangley Aronchick
- Skadden Arps
- Keker Van Nest & Peters
- Morgan Lewis
- Taus Cebulash
- Rusing Lopez
- Wilson Sonsini
- Cohen Milstein
- Kalikhman & Rayz
- Hutchings Barsamian
- Clark Hill
- Berger Montague
- Glancy Prongay
- Alston & Bird
- Milberg Coleman
- Partridge Snow
- Venable LLP
- Fine Kaplan
- Latham & Watkins
Companies
- Fraternal Order of Police
- Impax Laboratories, Inc.
- The Kroger Co.
- Ranbaxy
- Lupin Ltd.
- Medicis Pharmaceutical Corporation
- Rochester Drug Cooperative Inc.
- Optum Inc.
- United Food & Commercial Workers International Union
- Bausch Health Cos. Inc.
- OptumRx Inc.
- CVS Health Corp.
- Rite Aid Corp.
- H‑E‑B LP
- Teva Pharmaceutical Industries Ltd.
Sectors & Industries:
-
July 19, 2018
Class Attorneys Secure $40M From Solodyn Pay-For-Delay
A Massachusetts federal judge greenlighted more than $40 million in attorneys’ fees that consumers, pharmacies and health plans racked up during four years of multidistrict litigation and a three-week trial alleging several U.S. drugmakers colluded to delay a generic alternative to brand-name acne medication Solodyn.
-
June 04, 2018
End-Payor Attys Want $16M From $43M Medicis, Impax Deals
Motley Rice LLC and Hilliard & Shadowen LLP asked a Massachusetts federal judge Friday for a one-third cut plus $1.6 million in litigation expenses from $43 million in settlements they secured from Medicis Pharmaceutical Corp. and Impax Laboratories Inc. over the allegedly delayed launch of a generic acne medicine.
-
May 15, 2018
Class Attys Want $25M From $72.5M Medicis, Impax Deals
Lawyers for a class of direct drug purchasers asked a Massachusetts federal judge to approve nearly $25 million in attorneys' fees for securing $72.5 million worth of deals with Medicis Pharmaceutical Corp. and Impax Laboratories Inc. over the allegedly delayed launch of a generic acne medicine.
-
April 05, 2018
Impax's $20M Settlement In Pay-For-Delay Suit Clears Hurdle
A Massachusetts federal judge gave her initial approval Thursday to Impax Laboratories Inc.'s $20 million midtrial settlement with a class of consumers and insurers that claimed the lab delayed the launch of a generic acne medicine in exchange for a $40 million payment.
-
March 29, 2018
Impax Ends Acne Drug Pay-For-Delay Suit For $20M
Impax Laboratories Inc. on Thursday reached a $20 million midtrial settlement with a class of consumers and insurers, ending a suit in Massachusetts federal court that claimed the lab delayed the launch of a generic acne medicine in exchange for a $40 million payment.
-
March 26, 2018
CVS, Walgreens, Rite Aid Settle Impax Pay-For-Delay Suit
Amid a monthlong trial in Massachusetts federal court, Impax Laboratories Inc. reached a settlement with CVS, Walgreens, Rite Aid and others that cuts the retailers out of a group accusing it of agreeing to delay launching a generic version of an acne medication, according to a judge's order of dismissal filed Monday.
-
March 19, 2018
Acne Med Pay-For-Delay Deal Sped Up Generic, Exec Says
One of the architects of an Impax Laboratories Inc. deal panned as a pay-for-delay scheme by big retailers and a class of consumers told a Massachusetts federal jury Monday that the 2008 agreement with Medicis Pharmaceuticals Corp. actually rushed the generic version of an acne medication to the market ahead of schedule.
-
March 12, 2018
$40M Acne Med Pay-For-Delay Trial Kicks Off In Boston
A rare pay-for-delay trial kicked off Monday in a Massachusetts federal court with classes of consumers and big retailers such as CVS, Walgreens, Rite Aid and Safeway hammering Impax Laboratories Inc. over claims that it agreed to hold off on launching a generic version of acne medicine Solodyn in exchange for a $40 million payoff.
-
March 09, 2018
Impax Heads To Rare Trial In Pay-For-Delay Case
Impax Laboratories Inc. is set to face a Massachusetts jury Monday over allegations it received illegal reverse payments from Medicis Pharmaceutical Corp. to delay a generic form of acne medication Solodyn, one of just a handful of pay-for-delay cases to approach a verdict since the Supreme Court's landmark Actavis ruling in 2013.
-
March 09, 2018
FTC Materials Barred In Imminent Solodyn Pay-For-Delay Trial
An antitrust trial set to kick off Monday in Boston will not include Federal Trade Commission studies on the importance of generic brands to competition, a federal judge ruled days before jury selection, in a win for the one drugmaker still fighting the pay-for-delay case.